Journal article
Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.
Abstract
e18628
Background: In 2020, ASCO released a Provisional Clinical Opinion recommending universal hepatitis B virus (HBV) screening prior to systemic chemotherapy to reduce the risk of reactivation and associated morbidities. There is limited data for HBV prevalence and risk factors in gynecologic oncology. In gynecologic oncology patients at the Juravinski Cancer Centre, median baseline screening rate over 6 months was 0%. Our …
Authors
Mah SJ; Bellini J; Zhao L; Van Nguyen JM; Reade CJ; Jimenez W; Carlson V; Tyagi NJK; Bernard L; Pond GR
Journal
Journal of Clinical Oncology, Vol. 40, No. 16_suppl, pp. e18628–e18628
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2022
DOI
10.1200/jco.2022.40.16_suppl.e18628
ISSN
0732-183X